BR112013029713A2 - método de tratamento de distúrbios da visão - Google Patents

método de tratamento de distúrbios da visão

Info

Publication number
BR112013029713A2
BR112013029713A2 BR112013029713A BR112013029713A BR112013029713A2 BR 112013029713 A2 BR112013029713 A2 BR 112013029713A2 BR 112013029713 A BR112013029713 A BR 112013029713A BR 112013029713 A BR112013029713 A BR 112013029713A BR 112013029713 A2 BR112013029713 A2 BR 112013029713A2
Authority
BR
Brazil
Prior art keywords
treatment method
disorder treatment
vision disorder
treatment
disorders
Prior art date
Application number
BR112013029713A
Other languages
English (en)
Inventor
Craig Smith
Michael B Bartlett
yi-zhong Wang
Original Assignee
Novartis Ag
Vital Art And Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Vital Art And Science Inc filed Critical Novartis Ag
Publication of BR112013029713A2 publication Critical patent/BR112013029713A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
    • A61B5/0022—Monitoring a patient using a global network, e.g. telephone networks, internet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0077—Devices for viewing the surface of the body, e.g. camera, magnifying lens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/117—Identification of persons
    • A61B5/1171—Identification of persons based on the shapes or appearances of their bodies or parts thereof
    • A61B5/1172—Identification of persons based on the shapes or appearances of their bodies or parts thereof using fingerprinting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6887—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient mounted on external non-worn devices, e.g. non-medical devices
    • A61B5/6898—Portable consumer electronic devices, e.g. music players, telephones, tablet computers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient ; user input means
    • A61B5/742—Details of notification to user or communication with user or patient ; user input means using visual displays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient ; user input means
    • A61B5/7475—User input or interface means, e.g. keyboard, pointing device, joystick
    • A61B5/749—Voice-controlled interfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

resumo patente de invenção: "método de tratamento de distúrbios da visão". a presente invenção refere-se ao tratamento de distúrbios dos olhos. em particular, ela se refere ao uso de um sistema de monitoramento remoto para determinar a resposta do paciente ao tratamento terapêutico, em particular com antagonistas de vegf.
BR112013029713A 2011-05-27 2012-05-04 método de tratamento de distúrbios da visão BR112013029713A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490774P 2011-05-27 2011-05-27
PCT/US2012/036425 WO2012166287A1 (en) 2011-05-27 2012-05-04 Method of treating vision disorders

Publications (1)

Publication Number Publication Date
BR112013029713A2 true BR112013029713A2 (pt) 2016-09-06

Family

ID=46062771

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013029713A BR112013029713A2 (pt) 2011-05-27 2012-05-04 método de tratamento de distúrbios da visão

Country Status (16)

Country Link
US (1) US20140114208A1 (pt)
EP (1) EP2714734A1 (pt)
JP (1) JP2014516986A (pt)
KR (1) KR20140043351A (pt)
CN (1) CN103703025A (pt)
AU (1) AU2012262921A1 (pt)
BR (1) BR112013029713A2 (pt)
CA (1) CA2834373A1 (pt)
CL (1) CL2013003399A1 (pt)
CO (1) CO6811859A2 (pt)
IL (1) IL229192A0 (pt)
MX (1) MX2013013940A (pt)
RU (1) RU2013158328A (pt)
SG (1) SG194471A1 (pt)
TW (1) TW201249459A (pt)
WO (1) WO2012166287A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2013059331A1 (en) 2011-10-17 2013-04-25 Digisight Technologies, Inc. System and method for providing analysis of visual function using a mobile device with display
US9462941B2 (en) 2011-10-17 2016-10-11 The Board Of Trustees Of The Leland Stanford Junior University Metamorphopsia testing and related methods
WO2014194182A1 (en) 2013-05-31 2014-12-04 The Board Of Trustees Of The Leland Stanford Junior University Modular lens adapters for mobile anterior and posterior segment ophthalmoscopy
US11546527B2 (en) 2018-07-05 2023-01-03 Irisvision, Inc. Methods and apparatuses for compensating for retinitis pigmentosa
US11372479B2 (en) 2014-11-10 2022-06-28 Irisvision, Inc. Multi-modal vision enhancement system
WO2016154558A1 (en) 2015-03-25 2016-09-29 The Board Of Trustees Of The Leland Stanford Junior University Modular adapters for mobile ophthalmoscopy
US10188294B2 (en) 2015-06-18 2019-01-29 Verana Health, Inc. Adapter for retinal imaging using a hand held computer
JP2019501200A (ja) * 2016-01-08 2019-01-17 クリアサイド バイオメディカル，インコーポレイテッド 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス
JP6664115B2 (ja) * 2016-03-15 2020-03-13 原　英彰 アフリベルセプトによる網膜保護作用
RU2634009C1 (ru) * 2016-12-26 2017-10-23 Николай Игоревич Овечкин Способ определения степени нарушения зрения при витреоретинальных заболеваниях
US10413172B2 (en) 2017-12-11 2019-09-17 1-800 Contacts, Inc. Digital visual acuity eye examination for remote physician assessment
CA3091176A1 (en) 2018-02-13 2019-08-22 Frank Werblin Methods and apparatus for contrast sensitivity compensation
WO2019237033A1 (en) 2018-06-09 2019-12-12 Sensus Holistic Technologies, Llc Devices, systems and methods for self-administered therapy
US20220110542A1 (en) * 2020-10-08 2022-04-14 International Business Machines Corporation Multi-modal lung capacity measurement for respiratory illness prediction
CN112442534B (zh) * 2020-11-06 2022-03-15 温州医科大学 循环血外泌体miR-146a-5p作为视网膜静脉阻塞治疗及预后评估标志物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110112860A1 (en) * 2004-07-28 2011-05-12 Informedix, Inc. Medical treatment monitoring system and method
US8668334B2 (en) 2006-02-27 2014-03-11 Vital Art And Science Incorporated Vision measurement and training system and method of operation thereof
ES2390499T3 (es) * 2006-06-12 2012-11-13 Opko Pharmaceuticals, Llc Composiciones y métodos para la inhibición de la angiogénesis por sirna
US8066376B2 (en) 2008-05-01 2011-11-29 Vital Art & Science Incorporated Dynamic shape discrimination vision test
ES2908780T3 (es) 2009-05-09 2022-05-03 Genentech Inc Aparato portátil de examen de la visión y su calibración
KR20150068493A (ko) 2009-05-09 2015-06-19 바이탈 아트 앤드 사이언스, 엘엘씨. 형상 구별 시력 평가 및 추적 시스템
IN2012DN03361A (pt) * 2009-10-01 2015-10-23 Evonik Degussa Corp

Also Published As

Publication number Publication date
JP2014516986A (ja) 2014-07-17
AU2012262921A1 (en) 2013-11-21
CO6811859A2 (es) 2013-12-16
KR20140043351A (ko) 2014-04-09
CL2013003399A1 (es) 2014-09-05
US20140114208A1 (en) 2014-04-24
CA2834373A1 (en) 2012-12-06
CN103703025A (zh) 2014-04-02
SG194471A1 (en) 2013-12-30
IL229192A0 (en) 2013-12-31
NZ616353A (en) 2015-05-29
TW201249459A (en) 2012-12-16
RU2013158328A (ru) 2015-07-10
MX2013013940A (es) 2014-01-23
EP2714734A1 (en) 2014-04-09
WO2012166287A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
BR112013029713A2 (pt) método de tratamento de distúrbios da visão
HK1203478A1 (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
DK3574897T3 (da) Formulering med forlænget frigivelse, omfattende polymerproteinmikropartikler til anvendelse i øjets glaslegeme til behandling af vaskulære øjenlidelser
BR112015007758A2 (pt) dispositivo para um tratamento médico de uma esclera, método para tratar a esclera em um sujeito e método para tratar uma alteração patológica ou doença do olho.
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
MY171920A (en) Prevention and treatment of ocular conditions
MX2013000675A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
WO2009105534A3 (en) Ophthalmic nsaids as adjuvants
WO2013166037A9 (en) Non-retinoid antagonists for treatment of eye disorders
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
EA201390364A1 (ru) Средство для лечения синдрома сухого глаза, характеризующееся комбинированием агониста рецептора pyи гиалуроновой кислоты или ее соли, способ лечения синдрома сухого глаза и применение агониста рецептора pyи гиалуроновой кислоты или ее соли
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EP4272839A3 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
NZ713080A (en) Pyridin-4-yl derivatives
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
WO2014153385A3 (en) Methods of treating metabolic disorders
PL2774991T3 (pl) System dostarczania leków do stosowania w leczeniu lub diagnostyce zaburzeń neurologicznych
HUE038580T2 (hu) Hatóanyag bejuttató rendszer neurológiai rendellenességek kezelésében, vagy diagnózisában való felhasználásra
WO2014113384A8 (en) Lacrimal system drug delivery device

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]